{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:17:11Z","timestamp":1784027831112,"version":"3.55.0"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"0304","license":[{"start":{"date-parts":[[2014,1,12]],"date-time":"2014-01-12T00:00:00Z","timestamp":1389484800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>Minimal  residual disease (MRD) refers to the small number of malignant cells that  remain after therapy when the patient is in remission and shows no symptoms or  overt signs of disease. Current treatment protocols for haematological  malignancies allow most patients to obtain some form of MRD state, but cure  seldom follows and in most cases fatal relapses occur sooner or later, leaving  a bitter impression of having won a battle yet lost the war.\n        MRD  detection and quantification are used for evaluation of treatment efficiency, patient  risk stratification and long-term outcome prediction. Whereas multicolour flow  cytometry (MCFC) and polymerase chain reaction (PCR) based methods constitute  the two most commonly used techniques for MRD detection, next generation  sequencing will certainly be widely employed in the future.\n        As MRD  reflects the nature of the malignant disease itself, including its sensitivity  to the drug regimens applied, it constitutes the ideal method for surveillance and  patient follow-up. The morphological examination of peripheral blood or bone  marrow smears, although still an indispensable part of routine laboratory testing,  is clearly insufficient for patient management, and clinicians should not ask  themselves whether to look for MRD or not, but how and when.<\/jats:p>","DOI":"10.4414\/smw.2014.13907","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T09:32:03Z","timestamp":1404379923000},"page":"w13907","source":"Crossref","is-referenced-by-count":11,"title":["Minimal  residual disease monitoring: the new standard for treatment evaluation of haematological  malignancies?"],"prefix":"10.57187","volume":"144","author":[{"given":"Mathieu","family":"Hauwel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Matthes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36756","published-online":{"date-parts":[[2014,1,12]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1811\/2505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1811\/2506","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1811\/2505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:11:36Z","timestamp":1755234696000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/1811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,12]]},"references-count":0,"journal-issue":{"issue":"0304","published-online":{"date-parts":[[2014,1,13]]}},"URL":"https:\/\/doi.org\/10.4414\/smw.2014.13907","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,12]]}}}